RXRX(Recursion Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $10.18M | $39.84M | $44.58M | $58.84M | $74.68M |
| 毛利润 | $10.18M | −$8.43M | $1.99M | $13.60M | $3.73M |
| 营业利润 | −$182.78M | −$245.73M | −$350.06M | −$479.00M | −$648.13M |
| 净利润 | −$186.48M | −$239.48M | −$328.07M | −$463.66M | −$644.76M |
| 经营现金流 | −$158.61M | −$83.52M | −$287.78M | −$359.17M | −$371.81M |
| 自由现金流 | −$198.41M | −$120.58M | −$299.74M | −$372.87M | −$378.28M |
| 摊薄每股收益 | $-1.49 | $-1.36 | $-1.58 | $-1.69 | $-1.44 |